Table 1.
Body and muscle morphological parameters of the experimental groups.
| Variable | Group | |||||
|---|---|---|---|---|---|---|
| CON-NS | CON-LL | CON-LH | DEX-NS | DEX-LL | DEX-LH | |
| Initial BW (g) | 442.7 ± 5.90 | 442.2 ± 4.91 | 441.0 ± 4.35 | 443.8 ± 6.19 | 443.3 ± 4.19 | 444.8 ± 6.16 |
| Final BW (g) | 381.9 ± 22.1 b | 386.3 ± 20.32 b | 375.0 ± 10.21 b | 343.4 ± 11.53 a,b | 345.79 ± 15.89 a,b | 339.9 ± 11.73 a,b |
| Delta BW (g) | −60.8 ± 4.64 | −55.9 ± 5.36 | −65.17 ± 4.98 | −100.8 ± 2.40 a | −103.6 ± 2.08 a | −104.5 ± 3.35 a |
| Soleus (mg) | 214.8 ± 5.99 | 223.3 ± 5.45 | 221.0 ± 6.13 | 214.4 ± 4.29 | 210.8 ± 2.25 | 212.7 ± 5.45 |
| EDL (mg) | 189.4 ± 2.31 | 197.3 ± 2.08 | 200.1 ± 1.49 a | 179.6 ± 3.37 a | 174.8 ± 2.80 a | 174.6 ± 4.12 a |
Values are expressed as mean ± SE. Control non-supplemented group (CON-NS; n = 10); Control leucine supplemented group with low dose via gavage (CON-LL; n = 10); Control leucine supplemented group with high dose via gavage (CON-LH; n = 10); DEXA non supplemented group (DEX-NS; n = 10); DEXA treated group plus low dose of leucine supplementation via gavage (DEX-LL; n = 10); DEXA treated group plus high dose of leucine supplementation via gavage (DEX-LH; n = 10). BW—body weight; EDL—extensor digitorum longus. a p < 0.05 vs. CON-NS; b p < 0.05 vs. Initial BW.